Abstract
Although individually rare, inborn errors of metabolism represent a potentially preventable cause of death and disability. Tandem mass spectrometry allows a number of these disorders to be detected in a single step. Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is the most important of these disorders. However, public health decisions on whether or not to implement new screening programmes rely on evidence regarding benefits and harms. This article reviews existing published evidence for newborn screening for MCADD and highlights where further information is required for public health decision making. This review reveals that important uncertainties remain about performance and outcome, including criteria and thresholds for defining a positive screening result, diagnostic criteria, test performance and longer-term outcome. Notably, despite a combined experience of screening well over one million infants, there has been no report of a systematic follow-up of longer-term outcome in affected infants detected by screening. Prospective data on mortality, neurological outcome, and cognitive function are required to assess the effectiveness of screening. Additionally, the impact of screening and treatment on the families of infants with true, borderline, and false positive diagnoses needs to be taken into account.
Similar content being viewed by others
Abbreviations
- MCADD :
-
medium chain acyl-CoA dehydrogenase deficiency
References
Andresen BS, Dobrowolski SF, O’Reilly L, Muenzer J, McCandless SE, Frazier DM et al (2001) Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 68: 1408–1418
Atkinson K, Zuckerman B, Sharfstein JM, Levin D, Blatt RJ, Koh HK (2001) A public health response to emerging technology: expansion of the Massachusetts newborn screening program. Public Health Rep 116: 122–131
Boles RG, Buck EA, Blitzer MG, Platt MS, Cowan TM, Martin SK et al (1998) Retrospective biochemical screening of fatty acid oxidation disorders in postmortem livers of 418 cases of sudden death in the first year of life. J Pediatr 132: 924–933
Carpenter K, Wiley V, Sim KG, Heath D, Wilcken B (2001) Evaluation of newborn screening for medium chain acyl-CoA dehydrogenase deficiency in 275,000 babies. Arch Dis Child 85: F105–F109
Clayton PT, Doig M, Ghafari S, Meaney C, Taylor C, Leonard JV et al (1998) Screening for medium chain acyl-CoA dehydrogenase deficiency using electrospray ionisation tandem mass spectrometry. Arch Dis Child 79: 109–115
Dezateux C (1998) Evaluating newborn screening programmes based on dried blood spots: future challenges. Br Med Bull 54: 877–890
Dixon MA, Leonard JV (1992) Intercurrent illness in inborn errors of intermediary metabolism. Arch Dis Child 67: 1387–1391
Elliman D, Dezateux C, Bedford H (2002) Newborn and childhood screening programmes: criteria, evidence and current policy. Arch Dis Child 87: 6–9
Holtzman NA (1999) Are genetic tests adequately regulated? Science 286: 409
Iafolla AK, Thompson RJ, Roe CR (1994) Medium-chain-acyl-coenzyme A dehydrogenase deficiency; clinical course in 120 affected children. J Pediatr 124: 409–414
Kwon C, Farrell PM (2000) The magnitude and challenge of false-positive newborn screening test results. Arch Pediatr Adolesc Med 154: 714–718
Leonard JV, Dezateux C (2002) Screening for inherited metabolic disease in newborn infants using tandem mass spectrometry. BMJ 324: 4–5
Liebl B, Fingerhut R, Roschinger W, Muntau A, Knerr I, Olgemoller B et al (2000) Model project for updating neonatal screening in Bavaria: concept and initial results. Gesundheitswesen 62: 189–195
Peckham CS, Dezateux C (1998) Issues underlying the evaluation of screening programmes. Br Med Bull 54: 767–778
Pollitt RJ, Leonard JV (1998) Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UK. Arch Dis Child 79: 116–119
Pollitt RJ, Green A, McCabe ERB, Booth A, Cooper NJ (1997) Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technology Assessment 1: 1–202
Pourfarzam M, Morris A, Appleton M, Craft AW, Bartlett K (2001) Neonatal screening for MCAD deficiency: support from a retrospective study. Lancet 358: 1063–1064
Report of a Work Group (2001) Using tandem mass spectrometry for metabolic disease screening among newborns. Morb Mortal Weekly Report 50: 1–34
Seddon HR, Gray G, Pollitt RJ, Iitia A, Green A (1997) Population screening for the common G985 mutation causing medium-chain acyl-CoA dehydrogenase deficiency with Eu-labeled oligonucleotides and the DELFIA system. Clin Chem 43: 436–442
Seymour CA, Chalmers RA, Addison GM, Bain MD, Cockbern F, Littlejohns P et al (1997) Neonatal screening for inborn errors of metabolism: a systematic review. Health Technology Assessment 1: 1–95
Simonsen H, Jensen UG, Brandt NJ, Christensen E, Skovby F, Norgaard-Pedersen B (1999) Design of a pilot study to evaluate tandem mass spectrometry for neonatal screening. Southeast Asian J Trop Med Public Health 30[Suppl 2]: 166–169
Wald NJ (1994) Guidance on terminology. J Med Scr 1: 76
Wang SS, Fernhoff PM, Hannon WH, Khoury MJ (1999) Medium chain acyl-CoA dehydrogenase deficiency human genome epidemiology review. Genet Med 1: 332–339
Wang SS, Fernhoff PM, Khoury MJ (2000) Is the G985A allelic variant of medium-chain acyl-CoA dehydrogenase a risk factor for sudden infant death syndrome? A pooled analysis. Pediatrics 105: 1175–1176
Wilcken B (2001) Rare disease and the assessment of intervention: what sorts of clinical trials can we use? J Inherit Metab Dis 24: 291–298
Wilcken B, Hammond J, Silink M (1994) Morbidity and mortality in medium chain acyl coenzyme A dehydrogenase deficiency. Arch Dis Child 70: 410–412
Wilson CJ, Champion MP, Collins JE, Clayton PT, Leonard JV (1999) Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis. Arch Dis Child 80: 459–462
Ziadeh R, Hoffman EP, Finegold DN, Hoop RC, Brackett JC, Strauss AW et al (1995) Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res 37: 675–678
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dezateux, C. Newborn screening for medium chain acyl-CoA dehydrogenase deficiency: evaluating the effects on outcome. Eur J Pediatr 162 (Suppl 1), S25–S28 (2003). https://doi.org/10.1007/s00431-003-1346-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-003-1346-0